Maintenance chemotherapy for ovarian cancer - Wikidata - awgldk - TriplyDB

Maintenance chemotherapy for ovarian cancer

Maintenance chemotherapy for ovarian cancer

http://www.wikidata.org/entity/Q24201758

about

miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition Metastatic pancreatic cancer: Is there a light at the end of the tunnel?The expression of Duffy antigen receptor for chemokines by epithelial ovarian cancer decreases growth potential.Expression of BAF57 in ovarian cancer cells and drug sensitivity.EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.Ovarian cancer treatment: The end of empiricism?Differential Effects of Estradiol and Bisphenol A on SET8 and SIRT1 Expression in Ovarian Cancer Cells.Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.Failure of Elevating Calcium Induces Oxidative Stress Tolerance and Imparts Cisplatin Resistance in Ovarian Cancer Cells.Metronomics as maintenance treatment in oncology: time for chemo-switch.Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer.An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression.Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

P2860

Q28071987-7F48667D-C3DC-4975-8B26-B30A2CB7179F Q28082919-5482E390-E626-433C-A001-7F953FF06824 Q33750899-ACC5B9D7-5835-4CE2-80C5-5E053F1C9391 Q35538429-51BF3889-BF7C-43CE-B25B-52B6EAFCA122 Q35558444-E44BE548-EEF2-4ADC-9A05-9E1C421E2C53 Q35854285-10A07947-2011-4DC8-A371-2A2AF4A6F756 Q36225822-C813D25E-C8A9-4D07-8E16-CC0C63674D3E Q36554444-E66E2619-FD11-4364-B2F6-773A603FF5EA Q36796436-D9C5C1C5-8B43-47A4-BDF2-E901F7E7D744 Q36946741-6A3B5B3C-C1F8-42D7-973D-788B7AEF0F10 Q36983497-882571C5-098D-4A41-B14D-DA7C8B842530 Q37707573-AECCC574-D4D8-46A5-846D-017C608A0A86 Q41616541-00F370D4-089F-44EA-9666-3CDF7FF0722B Q42042730-5FF22ADC-8DB2-4E60-958E-AB3F5ABDB7F5 Q44718934-59135DAC-3045-48A1-97A2-DC16807C8DF7 Q52643918-B815C065-5272-4134-AA58-DF7CD9EF3180 Q59125756-9BF81A9E-BF3C-4B46-859A-FBE1F1CCD383

P2860

Maintenance chemotherapy for ovarian cancer

http://www.wikidata.org/entity/Q24201758

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Maintenance chemotherapy for ovarian cancer

@ast

Maintenance chemotherapy for ovarian cancer

@en

Maintenance chemotherapy for ovarian cancer

@en-gb

Maintenance chemotherapy for ovarian cancer

@nl

type

label

Maintenance chemotherapy for ovarian cancer

@ast

Maintenance chemotherapy for ovarian cancer

@en

Maintenance chemotherapy for ovarian cancer

@en-gb

Maintenance chemotherapy for ovarian cancer

@nl

prefLabel

Maintenance chemotherapy for ovarian cancer

@ast

Maintenance chemotherapy for ovarian cancer

@en

Maintenance chemotherapy for ovarian cancer

@en-gb

Maintenance chemotherapy for ovarian cancer

@nl

P1433

Q24201758-FB530391-E54D-416C-9A7D-4D240D6948B0

P1476

Q24201758-C4B88EC0-3BA2-4761-9B32-495D88312C48

P2093

Q24201758-09F2EE43-52A1-42EA-BE31-36FAA9E3AFCF

Q24201758-0F5F1E5D-5E74-4F5E-8758-2929EBF1E6F3

Q24201758-3DC7F068-83FA-4D91-878E-6E4B83B78D94

Q24201758-8C5CF00F-59BA-43B9-82A0-4200EE43C395

Q24201758-9A3C3711-A02D-4F37-BB16-E2A6173B611F

Q24201758-A3FE807B-995D-4883-95D3-0D95B5E88FE4

Q24201758-AB5367C0-F762-4E96-B8AD-1DAE3F7EE5D8

Q24201758-B72BC4CC-828D-4938-82CE-9ACA357FEE86

Q24201758-BA8FEC78-8042-4D6E-9217-5172D7CC1549

Q24201758-C6A27DC1-3958-4551-93EC-406DEC7CFCC9

P2860

Q24201758-05ED4262-0015-4228-846E-210FC73F2B40

Q24201758-2D9DD396-1025-436A-B8B2-55B1C70C423A

Q24201758-3FB54F31-9D5B-420E-AD6E-9E9D0821049B

Q24201758-49EFB7A7-0367-4E26-847A-4B50BE550CA1

Q24201758-7F46E87F-0858-4C28-A223-EE8DAC7F6587

Q24201758-8BC682F9-2B97-4F08-9F06-33E4D673C7FF

Q24201758-926C71E0-73CE-4C1C-AEC9-A592F845EAE9

Q24201758-A49F9808-6325-4695-B412-D8515C8E0F91

Q24201758-BB6F9391-FF34-4A0C-816A-D86D02289D96

Q24201758-CB3721A5-97D8-4579-8FE5-B9E5A68B77A9

P304

Q24201758-E144DAFB-B174-4B1A-ACDC-36504BB129AA

P31

Q24201758-0AD1E44C-5BD8-4C1C-B16B-C9476E34453F

Q24201758-c40acb2e-0f54-4863-99cf-88cb96ab0ecc

P3181

Q24201758-9184DC40-921E-4EC0-A5D7-D7D02D3E9A16

P356

Q24201758-FBE0B672-52DA-4CE0-A999-04975EE601E3

P433

Q24201758-55C56E41-CC3C-4BB8-A9DA-18C7C0B66A73

P577

Q24201758-68F9CE57-297D-4C97-B0C7-24CBD5D8D231

P698

Q24201758-37EF0564-6FCC-4A7C-99AE-853ED9F97B46

P921

Q24201758-8BE59F2B-EACC-413A-B168-C127444724CC

Q24201758-AFD51C0A-96DA-4D42-94F9-94379CD95AD7

P932

Q24201758-1DAFB090-06CF-4E26-9110-641D71C5BF03

P3181

P356

14651858.CD007414.PUB3

P1433

Cochrane Database of Systematic Reviews

P1476

Maintenance chemotherapy for ovarian cancer

@en

P2093

Dan Feng

http://www.w3.org/2001/XMLSchema#string

Dong Mei Wei

http://www.w3.org/2001/XMLSchema#string

Fang Fang

http://www.w3.org/2001/XMLSchema#string

Guan J Liu

http://www.w3.org/2001/XMLSchema#string

Huan Yu Xie

http://www.w3.org/2001/XMLSchema#string

Hui Chen

http://www.w3.org/2001/XMLSchema#string

Juan Zou

http://www.w3.org/2001/XMLSchema#string

Ling Mei

http://www.w3.org/2001/XMLSchema#string

Xu Han

http://www.w3.org/2001/XMLSchema#string

Xun Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance chemotherapy for ovarian cancer

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

Quantifying heterogeneity in a meta-analysis

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.

Ovarian cancer treatment: what is new.

First-line therapy for ovarian carcinoma: what's next?

P304

CD007414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1232854

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD007414.PUB3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23813336

http://www.w3.org/2001/XMLSchema#string

P921

P932

6457821

http://www.w3.org/2001/XMLSchema#string